Role of CCRL2 in lung DC trafficking. (A) Lung tissue and trachea were isolated from sensitized mice after one OVA-aerosol challenge. DCs were quantified by FACS analysis. Results are expressed as total number of DCs per mouse (mean ± SEM, n = 3; 6 mice/group). (B) The percentage of CD11c⁺/low autofluorescent DCs in total lung CD11c⁺ cells and DC subsets (CD103⁺, CD11b⁺, and Siglec H⁺/PDCA1⁺ pDCs) are presented. (C-D) OVA-sensitized mice received intratracheally 800 μg of OVA-FITC. (C) Representative analysis of WT and CCRL2^−/− mediastinal lymph node cells obtained 48 hours after FITC-OVA administration. (D) Kinetics of FITC⁺ DCs in lymph nodes. Data are mean ± SEM, n = 3; 12-15 mice/group. *P < .05. (E) Surface expression of CCRL2 in lymph node FITC⁺ and FITC⁻ WT DCs after OVA-FITC administration (n = 2; 4 mice/group). (F) Chemotaxis of bone marrow–derived DCs. One experiment representative of 6, each one performed with independent DC cultures. Results are at the net of basal migration (10 ± 3 and 8 ± 2 cells for WT and KO cells, respectively. *P < .05).